This August, Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) reported that their personalized cancer vaccine, intismeran autogene, cut the risk of melanoma recurrence after surgery when added to Keytruda. The result came from a phase 3 trial, the large final-stage study regulators lean on for approval. Moderna stock jumped 177% in one day and is up nearly 580% so far this year. Moderna has plenty more to prove: At FoolFest, our annual member event, Tom Gardner spoke with CEO Stéphane Bancel about the science, the stock reprice, and why he prefers the long-term game over the next quarter.
CryptoAlerta — análise de criptomoedas e mercado em tempo real